Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16569858 | 0.81 | MAOB (0.48) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL3537344 | 0.80 | RAB9A (0.60) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL9061932 | 0.78 | CA12 (0.64) | MAOBKDM4EALDH1A1GAACA12 | |
| SCHEMBL14863544 | 0.77 | NOS1 (0.50) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL16023545 | 0.77 | NOS1 (0.50) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL5410655 | 0.77 | ROCK2 (0.50) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL25921681 | 0.77 | MAOB (0.47) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL28814958 | 0.76 | MEN1 (0.48) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL5407397 | 0.76 | KCNH2 (0.49) | MAOBNOS1MEN1KMT2AROCK2 | |
| SCHEMBL4980408 | 0.76 | MAOB (0.52) | MAOBNOS1MEN1KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248998-A1 | LRRK2 Inhibitors | Brenig Therapeutics, Inc. | 2025-08-07 | — | — | US | disclosed |
| EP-4504722-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-1392292-B1 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | disclosed |
| EP-1513521-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2005-03-16 | — | — | EP | disclosed |
| EP-1392292-A4 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| EP-1392292-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | disclosed |
| WO-2003101379-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2003-12-11 | — | — | WO | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| WO-2002098350-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248998-A1 | LRRK2 Inhibitors | LRRK2, PARK7, PINK1 | MAOB 928/4885NOS1 3610/4885MEN1 3778/4885 |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | MAOB 454/4885NOS1 578/4885MEN1 2603/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | MAOB 244/4885NOS1 252/4885MEN1 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.